ClinicalTrials.gg

Program

envudeucitinib

Also written as “ESK-001”, “Envudeucitinib” and “Open-Label Envudeucitinib”.

Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Renal Insufficiency · Uveitis, Intermediate, led by Alumis.

Furthest: phase 3, since Aug 14, 202412 company-led studies, 3 open or runningNext primary completion: Dec 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alumis123 open or runningphase 3since Aug 14, 2024Mar 30, 2022Dec 1, 2027phase 2 · NCT05739435

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2022First study: phase 1 study in PharmacokineticsFirst studyNCT05330858 · 14 enrolled · United States
  2. Jun 9, 2022Phase 1 study in Safety and TolerabilityNCT05431634 · 49 enrolled · United States
  3. Oct 12, 2022Phase 2 study in Plaque PsoriasisNCT05600036 · 228 enrolled · United States, Canada, Czechia
  4. Feb 2, 2023Phase 2 study in Plaque PsoriasisNCT05739435 · 165 enrolled · United States, Canada
  5. Jun 29, 20232 phase 2 studiesNCT05966480, NCT05953688
  6. Aug 14, 2024Phase 3 study in Plaque PsoriasisNCT06586112 · 912 enrolled · United States, Australia, Bulgaria and more
  7. Sep 7, 2024Phase 3 study in Plaque PsoriasisNCT06588738 · 862 enrolled · United States, Austria, Canada and more
  8. Jan 27, 2025Phase 3 study in PsoriasisNCT06846541 · 1,680 enrolled · United States, Australia, Bulgaria and more
  9. Apr 22, 20252 phase 1 studiesNCT06952634, NCT06962774
  10. Dec 10, 2025Phase 1 study in Healthy VolunteerNCT07378579 · 52 enrolled · United States

Ahead

  1. Dec 1, 2027Primary completion: phase 2 study in Plaque PsoriasisNCT05739435
  2. Nov 2028Primary completion: phase 3 study in PsoriasisNCT06846541

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07378579Healthy Volunteer · United States1CompletedAug 31, 202452
NCT06962774Renal Insufficiency · United States1CompletedAug 1, 202516
NCT06952634Hepatic Impairment · United States1CompletedMar 24, 202632
NCT06846541Psoriasis · United States, Australia, Bulgaria and more3Active, not recruitingNov 20281,680
NCT06588738Plaque Psoriasis · United States, Austria, Canada and more3CompletedSep 23, 2025862
NCT06586112Plaque Psoriasis · United States, Australia, Bulgaria and more3CompletedSep 19, 2025912
NCT05966480Autoimmune Diseases · United States, Argentina, Bulgaria and more2Active, not recruitingJun 23, 2026408
NCT05953688Uveitis, Intermediate · United States2TerminatedAug 13, 202436
NCT05739435Plaque Psoriasis · United States, Canada2Active, not recruitingDec 1, 2027165
NCT05600036Plaque Psoriasis · United States, Canada, Czechia2CompletedJun 29, 2023228
NCT05431634Safety and Tolerability · United States1CompletedDec 1, 202249
NCT05330858Pharmacokinetics · United States1CompletedJun 30, 202214

How it is read

Names in the registry

  • “ESK-001”, 5 entries
  • “Envudeucitinib”, 3 entries
  • “envudeucitinib”, 2 entries
  • “Open-Label Envudeucitinib”, 1 entry
  • “Experimental drug: ESK-001”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.